Search Results
Your search for ASCO Post matches 17676 pages
Showing 5601 - 56502020 William Dameshek Prize Awarded to Adolfo Ferrando, MD, PhD
The American Society of Hematology (ASH) presented the 2020 William Dameshek Prize to Adolfo Ferrando, MD, PhD, of Columbia University Institute for Cancer Genetics in New York, for his outstanding research on the impact of NOTCH1 mutations on T-cell acute lymphoblastic leukemia (ALL). “I am...
ASH Awards Henry M. Stratton Medal to Hematology Researchers
The American Society of Hematology (ASH) recognized Michelle Le Beau, PhD, of the University of Chicago and the University of Chicago Medicine Comprehensive Cancer Center, and Maria Domenica Cappellini, MD, of the University of Milan in Italy, with the 2020 Henry M. Stratton Medal for their...
New Rules on Health-Care Price Transparency and Coverage for COVID-19 Vaccines
ON OCTOBER 28, the U.S. Department of Health and Human Services (HHS), the U.S. Department of Labor, and the U.S. Department of the Treasury released the coverage transparency final rule. Building on earlier administration actions requiring hospitals to disclose standard charges and negotiated...
Shilpi Gupta, MD, Joins Atlantic Health System Cancer Care’s Comprehensive Breast Health Program
Atlantic Health System Cancer Care recently announced that fellowship-trained medical oncologist Shilpi Gupta, MD, has joined Morristown Medical Center’s comprehensive breast health program, where her focus is breast oncology and research. Dr. Gupta is on staff at Atlantic Hematology Oncology at...
Albert Einstein College of Medicine Researchers Receive $5 Million Grant From the National Institutes of Health
A TEAM OF SCIENTISTS from Albert Einstein College of Medicine has received a 5-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate human immunodeficiency virus (HIV)- and human papillomavirus (HPV)-related cancers in Africa. The...
City of Hope Orange County Names Edward S. Kim, MD, MBA, Its Physician-in-Chief
CITY OF HOPE ORANGE COUNTY recently announced the appointment of cancer researcher and clinician Edward S. Kim, MD, MBA, as Senior Vice President and Vice Physician-in-Chief at City of Hope and Orange County Physician-in-Chief. “Dr. Kim has a depth and breadth of cancer expertise that is well...
Abraham Chachoua, MD, Announced as New Director of Perlmutter Cancer Center’s Lung Cancer Center
New York University (NYU) Langone Health’s Perlmutter Cancer Center recently appointed Abraham Chachoua, MD, as the new Director of Perlmutter Cancer Center’s Lung Cancer Center. Dr. Chachoua currently serves as the Jay and Isabel Fine Professor of Oncology and Professor of Urology at NYU...
World Health Organization Launches First-Ever Global Commitment to Eliminate Cervical Cancer
THE WORLD HEALTH ORGANIZATION (WHO) has launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, outlining three key steps: vaccination, screening, and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million...
Huntsman Cancer Institute Leadership Announces Two New Appointments
Huntsman Cancer Institute (HCI) at the University of Utah recently announced new leadership appointments for two long-standing cancer center members. Chief Academic Officer Brad Cairns, PhD, has accepted an appointment as Chief Academic Officer at HCI. In this new role, Dr. Cairns will lead...
The Problem of Heterogeneity Within Stage
The more senior of this duo grew up with prognostication by disease stage and was taught that all stage IV cancers behaved the same. In the past 3 decades, we have become much more cognizant of the heterogeneity in outcome within stage. Individual Kaplan-Meier plots by stage separate well but hide...
Staying a Step Ahead of Cancer
When I was diagnosed with metastatic breast cancer in 2018, my first thought was, I hope my three young children do not lose two parents to cancer. My husband, Ricky, had survived two bouts of cancer, early-stage colorectal cancer and, most recently, stage I kidney cancer. Like Ricky’s two...
Project Orbis: Partnering With International Regulatory Agencies to Bring Earlier Global Access to Novel Cancer Treatments
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Preeti Narayan, MD, a medical oncologist and clinical reviewer on the Breast and Gynecologic Disease Team,...
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, London, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib alone in first-line treatment ...
Bristol Myers Squibb Foundation and National Medical Fellowships Launch Program to Increase Diversity in Clinical Trials
The Bristol Myers Squibb Foundation and National Medical Fellowships recently announced their new partnership, which is aimed at improving diversity in clinical trials. Leveraging $100 million of the previously announced commitment to diversity and inclusion from Bristol Myers Squibb and the...
What Is the Measure of Minimal Residual Disease in AML?
Relapse is the primary obstacle to cure in leukemia. The term minimal residual disease (MRD) was coined in the early 1990s to describe finding a disease-specific marker in the context of a morphologic-appearing remission. The technique first used for MRD detection was the Southern blot (!), but the ...
Older Woman With Eye Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Facing Life’s Adversities, Even Cancer, From the Back of a Horse Named Buddy
“A bald eagle skims along the bluff where windblown Douglas firs, their exposed roots like talons, grip the eroding cliffs. Gulls circle and warn the bird of prey not to get too close. One hundred fifty feet below, the Salish Sea crashes and stretches west to the Pacific.” So begins Wild Ride Home: ...
Edward J. Benz, Jr, MD, Receives 2020 ASH Award for Leadership in Promoting Diversity
The 2020 American Society of Hematology (ASH) Award for Leadership in Promoting Diversity was awarded to Edward J. Benz, Jr, MD, President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School. Dr....
Addressing Disparities in Care Among Black Men and Women With Cancer
The American Cancer Society and Pfizer have approved grants totaling more than $3.7 million focused on reducing racial disparities in care and helping to optimize cancer outcomes for Black men and women in 10 communities. The goal is to address systemic race-related barriers and disparities in the...
The Lung Microbiome May Affect Lung Cancer Pathogenesis and Prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.1 “The...
Dana-Farber/Brigham and Women’s Cancer Center and Stamford Hospital Expand Collaboration
Stamford Health and Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) formally announced an exclusive, expanded collaboration to increase access to DF/BWCC experts and resources for patients at Stamford Health’s Carl & Dorothy Bennett Cancer Center. Stamford Health first joined the...
Understanding Breast Cancer Diagnosis and Treatment Disparities in Resource-Challenged Nations
Cancer is the second leading cause of death in the Caribbean. Adding to this growing burden, many of the nations in this geographically spread region have under-resourced health-care systems and a lack of cohesive approaches to the delivery of cancer care. To shed light on the public health...
Researchers Join $10 Million Project to Better Understand Sex Differences in Brain Cancer Outcomes
Researchers from Penn State College of Medicine are participating in a $10 million project to better understand why men and women with a common and deadly type of brain cancer have different survival rates. The investigators hope the study results can be used to develop new therapeutic approaches...
ASH Recognizes Admiral Brett Giroir, MD, With 2020 Outstanding Service Award
The American Society of Hematology (ASH) honored Admiral Brett Giroir, MD, Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS), for his outstanding support of hematology research and patient care. At the all-virtual annual meeting, Admiral Giroir received the...
Hannah Hazard-Jenkins, MD, Named Permanent Director of the WVU Cancer Institute
Hannah Hazard-Jenkins, MD, Associate Chair of Surgery for Cancer Services, has been named permanent Director of the West Virginia University (WVU) Cancer Institute after having served in the position on an interim basis since January. “As a native West Virginian, it is my honor to serve in this...
Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, Receives Inaugural AACR Scientific Achievement Award Established in His Honor
The American Association for Cancer Research (AACR) recently announced that Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, will receive the inaugural AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research. Dr. Von Hoff is being recognized for his...
FDA and AACR Launch Project Livin’ Label
The American Association for Cancer Research (AACR) and the U.S. Food and Drug Administration (FDA) will collaborate on Project Livin’ Label, a new educational initiative that aims to foster broad understanding of specific oncology product labels and increase awareness of recent oncology drug FDA...
Erratum
In the November 10, 2020, issue of The ASCO Post, the article “Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile” contained errors with regard to the head shots of the coauthors. A photo of Augusto León G-H, MD (the son of another coauthor with a similar name), was...
Discerning the Underlying Mechanisms of Endometrial Cancer Disparities in Black Women
Endometrial cancer is the fourth most common cancer diagnosed in the United States, and the seventh most common cause of cancer death among women.1 This year, nearly 66,000 women will be diagnosed with the cancer, and about 12,600 will die of the disease.2 And although endometrial cancer is one of...
SABCS 2020: Patients With Breast Cancer Undergoing Radiotherapy May Have Underrecognized Side Effects
Among patients with breast cancer treated with radiotherapy, symptoms were commonly underrecognized in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom underrecognition. These findings were reported by Reshma...
CU Cancer Center Leukemia Researcher Receives NCI Outstanding Investigator Award
Craig Jordan, PhD, University of Colorado (CU) Cancer Center member and Chief of the Hematology Division in the CU School of Medicine, was awarded a 2020 National Cancer Institute (NCI) Outstanding Investigator Award. This 7-year grant supports investigators with outstanding records of...
SABCS 2020: Opioid and Sedative-Hypnotic Use After Mastectomy With Reconstructive Surgery
Women who undergo mastectomy with reconstructive surgery as part of breast cancer treatment may face the risk of persistent use of opioids and sedative-hypnotic drugs, according to data presented by Jacob Cogan, MD, and colleagues at the 2020 San Antonio Breast Cancer Symposium (Abstract GS3-08)....
SABCS 2020: Meta-analysis of Pregnancy Outcomes in Breast Cancer Survivors
A large meta-analysis of breast cancer survivors of childbearing age indicated that they are less likely than the general public to become pregnant and may face a higher risk of certain complications, such as preterm labor. However, most survivors who do become pregnant deliver healthy babies and...
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Neoplasms
The ASCO Post is pleased to present the Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore extranodal marginal zone lymphoma of mucosa-associated lymphoid neoplasms (MALT lymphomas). For each quiz...
SABCS 2020: Radiotherapy Omission After Breast-Conserving Surgery for Older Patients With HR-Positive Breast Cancer
Patients aged 65 or older with hormone receptor (HR)-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according ...
Assessing the Progress Made in Global Cancer Care and Looking Toward the Future
In October 2020, Her Royal Highness Princess Dina Mired of Jordan ended her 2-year tenure as President of the Union for International Cancer Control (UICC), a global organization with more than 1,198 members from 172 countries and territories committed to reducing the cancer burden and...
ASCO Issues Comprehensive Recommendations to Strengthen Cancer Care and Research During and Beyond the COVID-19 Pandemic
On December 8, ASCO issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care...
Caron A. Jacobson, MD, on Treating Large B-Cell Lymphoma With Axicabtagene Ciloleucel
Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses results from the ZUMA-9 C2 study, an ongoing trial that is exploring axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma (Abstract 2100).
Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies
Matthew S. Davids, MD, of Dana-Farber Cancer Institute, summarizes three key studies from a session he co-moderated on ibrutinib plus venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), long-term responses to these agents for ...
David T. Teachey, MD, on Pediatric Leukemia and Lymphoma: New Findings on Cranial Radiation and Bortezomib
David T. Teachey, MD, of the University of Pennsylvania and Children’s Hospital of Philadelphia, discusses data showing that cranial radiation might be eliminated in most children with T-cell acute lymphoblastic leukemia and that bortezomib may improve survival in children with T-cell lymphoblastic ...
ASH 2020: Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL
Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 464) showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab...
Jyoti Nangalia, MBBChir, on MPN: A New Paradigm for the Development of Blood Cancer?
Jyoti Nangalia, MBBChir, of Wellcome Sanger Institute and the University of Cambridge, discusses how her team used large-scale whole-genome sequencing to precisely time the origins of a blood cancer and measure how it grew. The information could provide opportunities for early diagnosis and...
Sagar Lonial, MD, on CAR T-Cell Therapies for Myeloma: Novel Approaches and Longer-Term Follow-up Data
Sagar Lonial, MD, of the Emory University School of Medicine, summarizes key papers presented in a session he co-moderated on how second-generation CAR T cells can be used to treat patients with multiple myeloma (Session 653).
ASH 2020: Role of Venetoclax in High-Risk Myeloid Malignancies
The BCL2 inhibitor venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers, and in early studies, the combination showed improved outcomes, according to two reports presented by Jacqueline S. Garcia, MD, and colleagues at the 2020 American Society of Hematology ...
ASH 2020: Subcutaneous Teclistamab for Relapsed or Refractory Multiple Myeloma Studied in Phase I Trial
A subcutaneous injection of the BCMAxCD3 bispecific antibody teclistamab was found to be safe and elicited responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study presented by Alfred L. Garfall, MD, and...
ASH 2020: Environmental Surface Testing for Presence of SARS-CoV-2 in Inpatient and Outpatient Hematology/Oncology Settings
A research team from Rutgers Cancer Institute of New Jersey evaluated the presence of SARS-CoV-2 on various environmental surfaces in outpatient and inpatient hematology/oncology settings. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient...
Curtis Lachowiez, MD, on AML: Venetoclax in Combination With Standard Intensive Induction/Consolidation Therapy
Curtis Lachowiez, MD, of The University of Texas MD Anderson Cancer Center, discusses an interim analysis of a phase Ib/II study showing that venetoclax plus chemotherapy represents an effective regimen, particularly in patients with newly diagnosed and relapsed or refractory acute myeloid...
Mohandas Narla, DSc, Receives 2020 Wallace H. Coulter Award for Lifetime Achievement in Hematology
The American Society of Hematology (ASH) presented Mohandas Narla, DSc, of the New York Blood Center, with the 2020 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Narla is being recognized for his significant contributions to hematology through his groundbreaking research, his ...
2020 Ernest Beutler Lecture and Prize Presented to Ari Melnick, MD, and Courtney DiNardo, MD
The American Society of Hematology (ASH) will honor Ari Melnick, MD, of Weill Cornell Medicine in New York, and Courtney DiNardo, MD, of the University of Texas MD Anderson Cancer Center, with the 2020 Ernest Beutler Lecture and Prize for their significant research contributions to the treatment...
ASH 2020: Novel Antibody-Drug Conjugate Shows Activity in Rare, Aggressive Form of Leukemia
A phase I/II study found that IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but aggressive form of leukemia. Treatment with the...
